FDA, DOH NANINDIGANG WALANG KASO NG BLOOD CLOTTING MULA SA BAKUNANG GAWA NG ASTRAZENECA

Ni Monica N. Ladisla
Source: PIA
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Wala pa umanong matibay na ebidensya na may kinalaman ang bakunang gawa ng AstraZeneca sa pagkakaroon umano ng blood clotting sa mga nakatanggap nito, ayon sa Food and Drug Administration (FDA).

Ito ay matapos pansamantalang suspendihin ng Department of Health (DOH) kamakailan ang pagbibigay ng naturang bakuna sa mga may edad 59 taong gulang pababa.

“So far po, ang ating national adverse events following immunization committee sumulat kahapon na wala naman daw na any cases reported ng blood clotting na connected sa bakuna dito sa atin,” pahayag ni  FDA Director General Eric Domingo.

Ayon pa kay Domingo, naghihintay pa umano sila sa kasalukuyan ng karagdagang impormasyon mula sa vaccine expert panel ng bansa gayundin sa World Health Organization.  

“Hindi naman natin tinigil sa senior citizen. Sabi lang natin ‘yung 59 and below tingnan muna natin ang datos para lang may complete information ang magbabakuna at babakunahan,” paglilinaw ni Domingo.

Nilinaw din ni DOH Undersecretary Maria Rosario Vergeire na maaari umanong magkaroon ng extra indication o precaution sa paggamit ng AstraZeneca.

“Hindi ho natin tinitigil, nu’ng nangyari ‘yan sa ibang bansa, sinabi ng mga eksperto, and even the WHO [that] the benefit still outweighs the risk. So, ibig sabihin itutuloy pa rin, kailangan lang ho better guided ang mga gagamit,” ani Usec. Vergeire.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.